Combined cancer registry data from all VHA facilities. Includes North American Association of Central Cancer Registries, Inc. (NAACCR).

• The global industry was valued at US$ 2.3 Bn in 2023
• It is projected to advance at a CAGR of 11.0% from 2024 to 2034 and reach more than US$ 7.4 Bn by the end of 2034

Market Introduction

Attribute	Detail
Drivers	Precision Cancer Care Facilitated Process Scale-up and Versatility in Research Surge in Incidence of Lung Cancer

Regional Outlook of Molecular Oncology Industry

Attribute	Detail
Leading Region	North America

Molecular Oncology Market Snapshot

Attribute	Detail
Market Value in 2023	US$ 2.3 Bn
Forecast (Value) in 2034	US$ 7.4 Bn
Growth Rate (CAGR)	11.0%
Forecast Period	2024-2034
Historical Data Available for	2020-2022
Quantitative Units	US$ Mn for Value
Market Analysis	It provides segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape	Market share analysis by company (2022) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Market Segmentation	Product Instruments Reagents Others Cancer Type Lung Cancer Breast Cancer Colorectal Cancer Ovarian Cancer Pancreatic Cancer Others Technology PCR (rt-PCR, d-PCR) NGS (Next Generation Sequencing) Microarray FISH (Fluorescent in situ-hybridization) Others End-user Hospitals and Clinics Diagnostic Laboratories Cancer Centers and Specialty Clinics Others (Government and Public Health Agencies)
Regions Covered	North America Latin America Europe Asia Pacific Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain China India Japan Australia & New Zealand Brazil Mexico South Africa GCC Countries
Companies Profiled	Roche Diagnostics Thermo Fisher Scientific Inc. Illumina, Inc. Qiagen N.V. Agilent Technologies, Inc. Abbott Laboratories Bio-Rad Laboratories, Inc. Myriad Genetics, Inc. Genomic Health, Inc. Other Players
Customization Scope	Available upon request
Pricing	Available upon request

Both medical care and observational studies in oncology require a thorough understanding of a patient's disease progression and treatment history, often elaborately documented within clinical notes. As large language models (LLMs) are becoming more popular, it becomes important to evaluate their potential in oncology. However, no current information representation schema fully encapsulates the diversity of oncology information within clinical notes, and no comprehensively annotated oncology notes exist publicly, thereby limiting a thorough evaluation. We curated a new fine-grained, expert-labeled dataset of 40 de-identified breast and pancreatic cancer progress notes at University of California, San Francisco, and assessed three recent LLMs (GPT-4, GPT-3.5-turbo, and FLAN-UL2) in zero-shot extraction of detailed oncological information from two narrative sections of clinical progress notes. Model performance was quantified with BLEU-4, ROUGE-1, and exact match (EM) F1-score evaluation metrics. Our team of oncology fellows and medical students manually annotated 9028 entities, 9986 modifiers, and 5312 relationships. The GPT-4 model exhibited overall best performance, with an average BLEU score of 0.73, an average ROUGE score of 0.72, an average EM-F1-score of 0.51, and an average accuracy of 68% (expert manual evaluation on 20 notes). GPT-4 was proficient in tumor characteristics and medication extraction, and demonstrated superior performance in inferring symptoms due to cancer and considerations of future medications. Common errors included partial responses with missing information and hallucinations with note-specific information. LLMs are promising for performing reliable information extraction for clinical research, complex population management, and documenting quality patient care, but there is a need for further improvements.

Introduction

Global Precision Oncology Market size is expected to be worth around USD 202.5 Billion by 2032 from USD 89.3 Billion in 2023, growing at a CAGR of 9.8% during the forecast period from 2024 to 2032.

Precision medicine represents a transformative approach to healthcare, focusing on customizing medical treatment to individual patient profiles, particularly in oncology. This field combines advances in biotechnology, digital healthcare, and substantial public investment to evolve personalized therapies for diseases like cancer. Precision oncology, a primary subset of precision medicine, aims to match each cancer patient with the most effective treatment based on their unique genetic makeup, enhancing treatment efficacy and patient outcomes.

The precision oncology market is poised for significant growth, driven by increasing demand for personalized cancer treatments. Such treatments not only empower patients with better information but also increase their engagement and control over their health decisions. This, in turn, leads to better health outcomes, improved revenues for healthcare providers, and enhanced relationships between patients and therapists. The integration of AI, big data analytics, and digital health technologies is expected to further enhance these outcomes and accelerate the pace of drug development.

The market, however, faced setbacks during the COVID-19 pandemic due to social distancing and lockdowns, which slowed down clinical trials and reduced patient visits to healthcare facilities for precision oncology care. Despite these challenges, the field is recovering, with ongoing research, early detection efforts, and improving prognosis methods driving the demand for precision oncology services.

Globally, the approach to cancer management varies significantly. A WHO survey indicates that only 39% of surveyed countries include basic cancer management in their publicly financed health services, and just 28% provide broader palliative care.

In terms of epidemiology, 2022 saw approximately 20 million new cancer cases and 9.7 million deaths worldwide. The data also shows that roughly 53.5 million people were living within five years of a cancer diagnosis, highlighting the widespread impact of the disease. The statistics further reveal that about one in five people develop cancer during their lifetime, with men facing a higher mortality rate compared to women.

https://market.us/wp-content/uploads/2023/04/Precision-Oncology-Market-size.jpg" alt="Precision Oncology Market size" class="wp-image-99452">

Lung Cancer Dataset

## Overview

Lung Cancer Dataset is a dataset for object detection tasks - it contains Test annotations for 8,590 images.

## Getting Started

You can download this dataset for use within your own projects, or fork it into a workspace on Roboflow to create your own model.

  ## License

  This dataset is available under the [CC BY 4.0 license](https://creativecommons.org/licenses/CC BY 4.0).

SESCD oncology data is recorded and curated by a dedicated team of clinical coders using paper-based patient case notes, electronic patient records, Scottish morbidity registers, and secondary healthcare databases. In addition, there are a number of automatic feeds from various national, regional and bespoke databases and EPRs which are quality checked by the coding team. Clinical expertise is provided by a dedicated team of clinical and research professionals.

The Oncology Clinical Trials Market Report Segments the Industry Into by Phase (Phase I, Phase II, Phase III, Phase IV), Design (Treatment Studies and Observational Studies), Cancer Type (Lung Cancer, Breast Cancer, and More), Therapeutic Modality (Immunotherapy, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Cancer Rates for Lake County Illinois. Explanation of field attributes: Colorectal Cancer - Cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine). This is a rate per 100,000. Lung Cancer – Cancer that forms in tissues of the lung, usually in the cells lining air passages. This is a rate per 100,000. Breast Cancer – Cancer that forms in tissues of the breast. This is a rate per 100,000. Prostate Cancer – Cancer that forms in tissues of the prostate. This is a rate per 100,000. Urinary System Cancer – Cancer that forms in the organs of the body that produce and discharge urine. These include the kidneys, ureters, bladder, and urethra. This is a rate per 100,000. All Cancer – All cancers including, but not limited to: colorectal cancer, lung cancer, breast cancer, prostate cancer, and cancer of the urinary system. This is a rate per 100,000.

The global AI in oncology market size was valued at USD 1.1 billion in 2023 to USD 9.1 billion by 2035, with a noteworthy CAGR of 21.4%.

This statistic displays the top oncology products worldwide by projected market share for 2024, and their market shares in 2017. Cancer drug Opdivo from Bristol-Myers Squibb and Ono Pharmaceutical is expected to keep its position with a market share of five percent. Top oncology productsOncological products generate a significant proportion of their revenue in the United States and in Europe. In 2012, oncology spending totaled nearly 50 billion U.S. dollars in the United States and 22 billion U.S. dollars in the leading five EU-countries. Oncology is among the top therapy classes in the pharmaceutical market. Among the top oncology products in 2017 were Keytruda and Opdivo, generating 3.8 and 5.7 billion U.S. dollars on the worldwide market. Top cancer drug Rituxan is marketed by Roche and is used to treat diseases such as lymphomas, leukemias, transplant rejections, and autoimmune disorders. Bevacizumab, marketed as Avastin also under Roche, is used to slow down the growth rate of new blood vessels. It can be used to treat cancers such as those originating in the colorectum, lung, breast, or kidney. Roche has a stronghold on the global oncology market. In 2017, Roche maintained a share of over 26 percent of the market but is expected to drop to some 12 percent of the market in 2024. Roche or Hoffman-La Roche is a Swiss company that was founded in 1896. The company focuses primarily on pharmaceutical products and diagnostics. Roche generated more than 53 billion Swiss francs in revenue in 2017, making it one of the most successful biotech and pharmaceutical companies in the world.

The Precision Oncology Market report segments the industry into By Type (Therapeutics, Diagnostics), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Cancer Types), By End-User (Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Research & Academic Institutes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).

• The global industry was valued at US$ 6.1 Bn in 2023
• It is expected to grow at aCAGR of 9.5% from 2024 to 2034 and reach US$ 17.0 Bn by the end of 2034

Market Introduction

Attribute	Detail
Market Drivers	Increase in Demand for Targeted Medicines Integration of Artificial Intelligence (AI) in Companion Diagnostics

Regional Outlook

Attribute	Detail
Leading Region	North America

Companion Diagnostic Tests in Oncology Market Snapshot

Attribute	Detail
Market Size in 2023	US$ 6.1 Bn
Market Forecast (Value) in 2034	US$ 17.0 Bn
Growth Rate (CAGR)	9.5%
Forecast Period	2024-2034
Historical Data Available for	2020-2022
Quantitative Units	US$ Bn for Value
Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape	Market share analysis by company (2023) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Market Segmentation	By Detection Technique Protein Detection Immunohistochemistry DNA Detection Polymerase Chain Reaction (PCR) Next-generation Sequencing (NGS) In Situ Hybridization Others By Biomarker EGFR KRAS HER2 BRAF V600E Others By Cancer Type Breast Cancer Lung Cancer Colorectal Cancer Liver Cancer Melanoma Others By End-user Hospitals Specialty Clinics Diagnostic Labs Others
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain China India Japan Australia & New Zealand Brazil Mexico South Africa GCC
Companies Profiled	Abbott F. Hoffmann-LA Roche AG Genomic Health, Inc. QIAGEN Agilent Technologies, Inc. AGENDIA N.V. bioMérieux SA Illumina, Inc. Siemens Healthineers Thermo Fisher Scientific Inc. BioGenex
Customization Scope	Available Upon Request
Pricing	Available Upon Request

This statistic displays the share of breakthrough therapy requests granted by the FDA, by therapeutic area, in the United States, as of 2019. As of end-September of that year, 32 percent of requests for breakthrough therapies granted came from the oncology area. The FDA recommends that submissions for breakthrough therapy designations should be made prior to phase III.

Clinically annotated database of all patients seen in the Oncology Dept and/or presented at a Cancer Multidisciplinary meeting at SVHM. Details pertaining to the diseasse, treatment and outcome are included.

The global oncology information system market is set to witness a high growth rate of 8% in the next 5 years. Rising incidence of cancer, growing need to curtail the cost of oncology care, continuous advancements in healthcare IT, government initiatives aimed at improving cancer care and mandates to support oncology information systems, growing focus […]

Breast Cancer Wisconsin Diagnostic Dataset

Following description was retrieved from breast cancer dataset on UCI machine learning repository. Features are computed from a digitized image of a fine needle aspirate (FNA) of a breast mass. They describe characteristics of the cell nuclei present in the image. A few of the images can be found at here. Separating plane described above was obtained using Multisurface Method-Tree (MSM-T), a classification method which uses linear… See the full description on the dataset page: https://huggingface.co/datasets/scikit-learn/breast-cancer-wisconsin.

Background: Extracting inclusion and exclusion criteria in a structured, automated fashion remains a challenge to developing better search functionalities or automating systematic reviews of randomized controlled trials in oncology. The question “Did this trial enroll patients with localized disease, metastatic disease, or both?†could be used to narrow down the number of potentially relevant trials when conducting a search. Dataset collection: 600 randomized controlled trials from high-impact medical journals were classified depending on whether they allowed for the inclusion of patients with localized and/or metastatic disease. The dataset was randomly split into a training/validation and a test set of 500 and 100 trials respectively. However, the sets could be merged to allow for different splits. Data properties: Each trial is a row in the csv file. For each trial there is a doi, a publication date, a title, an abstract, the abstract sections (introduction, methods, results, conclus..., Randomized controlled oncology trials from seven major journals (British Medical Journal, JAMA, JAMA Oncology, Journal of Clinical Oncology, Lancet, Lancet Oncology, New England Journal of Medicine) published between 2005 and 2023 were randomly sampled and annotated with the labels “LOCAL†, “METASTATIC†, both or none. Trials that allowed for the inclusion of patients with localized disease received the label “LOCAL†. Trials that allowed for the inclusion of patients with metastatic disease received the label “METASTATIC†. Trials that allowed for the inclusion of patients with either localized or metastatic disease received bot labels. Screening trials that enrolled patients without known cancer or trials of interventions to prevent cancer were assigned no label. Trials of tumor entities where the distinction between localized and metastatic disease is usually not made (e.g., hematologic malignancies) were skipped. Annotation was based on the title and abstract. If those were inconclusiv..., , # Randomized controlled oncology trials with tumor stage inclusion criteria

https://doi.org/10.5061/dryad.g4f4qrfzn

600 randomized controlled oncology trials from high-impact medical journals (British Medical Journal, JAMA, JAMA Oncology, Journal of Clinical Oncology, Lancet, Lancet Oncology, New England Journal of Medicine) published between 2005 and 2023**Â **were randomly sampled and classified depending on whether they allowed for the inclusion of patients with localized and/or metastatic disease. The dataset was randomly split into a training/validation and a test set of 500 and 100 trials respectively. However, the sets could be merged to allow for different splits.

Description of the data and file structure

Each trial is a row in the csv file. For each trial there are the follwing columns:

• doi:Â Digital Object Identifier of the trial
• date: Publication data according to PubMed
• title: Title of the trial according to PubMed
• ab...

The Iraq-Oncology Teaching Hospital/National Center for Cancer Diseases (IQ-OTH/NCCD) lung cancer dataset was collected in the above-mentioned specialist hospitals over a period of three months in fall 2019. It includes CT scans of patients diagnosed with lung cancer in different stages, as well as healthy subjects. IQ-OTH/NCCD slides were marked by oncologists and radiologists in these two centers. The dataset contains a total of 1190 images representing CT scan slices of 110 cases (see Figure 1). These cases are grouped into three classes: normal, benign, and malignant. of these, 40 cases are diagnosed as malignant; 15 cases diagnosed with benign; and 55 cases classified as normal cases. The CT scans were originally collected in DICOM format. The scanner used is SOMATOM from Siemens. CT protocol includes: 120 kV, slice thickness of 1 mm, with window width ranging from 350 to 1200 HU and window center from 50 to 600 were used for reading. with breath hold at full inspiration. All images were de-identified before performing analysis. Written consent was waived by the oversight review board. The study was approved by the institutional review board of participating medical centers. Each scan contains several slices. The number of these slices range from 80 to 200 slices, each of them represents an image of the human chest with different sides and angles. The 110 cases vary in gender, age, educational attainment, area of residence and living status. Some of them are employees of the Iraqi ministries of Transport and Oil, others are farmers and gainers. Most of them come from places in the middle region of Iraq, particularly, the provinces of Baghdad, Wasit, Diyala, Salahuddin, and Babylon.

The oncology database was established in 2019 building on 40+ years of data collection across the region of the South East Scotland Cancer Network. The database holds data on diagnosis, treatment and outcomes of patients undergoing care within the region.

The global market for Cancer Registry Data Management Software is experiencing robust growth, driven by the increasing incidence of cancer globally, the rising demand for efficient data management solutions within healthcare systems, and the growing emphasis on population-based cancer registries for research and public health initiatives. The market's Compound Annual Growth Rate (CAGR) is estimated to be around 8% during the forecast period (2025-2033), indicating substantial expansion. Key drivers include the need for improved data accuracy and interoperability, the increasing adoption of electronic health records (EHRs), and the growing need for advanced analytics to support cancer research, treatment planning, and resource allocation. The market is segmented by deployment type (cloud-based and on-premise), by end-user (hospitals, research institutions, government agencies), and by geography. Leading players, such as Onco, C/Net Solutions, Elekta AB, Rocky Mountain Cancer Data Systems, Electronic Registry Systems, and McKesson Corporation, are actively investing in developing innovative solutions and expanding their market reach through strategic partnerships and acquisitions. This competitive landscape fuels innovation, resulting in the development of user-friendly interfaces, advanced reporting capabilities, and robust security features within the software. The market's growth is also influenced by several restraints. These include the high cost of implementation and maintenance of such software, the complexity of integrating with existing healthcare IT infrastructure, and the need for skilled personnel to operate and manage the systems. However, the long-term benefits of improved data management, enhanced research capabilities, and optimized resource allocation are expected to outweigh these challenges, leading to continued market expansion. The North American market currently holds a significant share, driven by advanced healthcare infrastructure and substantial investments in cancer research. However, emerging economies in Asia-Pacific and other regions are demonstrating strong growth potential, driven by rising cancer rates and increasing healthcare spending. The forecast period (2025-2033) reflects a period of continued growth, with the market expected to reach a substantial size by 2033 due to the factors mentioned above.